Amalgamation of Takeda Canada Inc. and Shire Pharma Canada ULC Solidifies Company’s Leadership Position in Canadian Biopharmaceutical Industry
Updated COVID-19 Healthcare Professional Letter
Self-injectable formulation of ENTYVIO® (vedolizumab) approved in Canada for the maintenance treatment of moderately to severely active ulcerative colitis
COVID-19 HCP Letter
Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre
© 2020 Takeda Canada Inc. All rights reserved.
You are about to leave the Takeda Canada website. This link is provided by Takeda as a resource to website visitors. Takeda Canada does not endorse or take responsibility for information presented on any website except its own.
Do you wish to leave this site?